companiesandmarkets.com

Return to Report | Print

Lev Pharmaceuticals Inc - Premium Company Profile

http://www.companiesandmarkets.com/Summary-Company-Profile/lev-pharmaceuticals-inc-premium-company-profile-42820.asp

Report Summary

Introduction

Lev Pharmaceuticals is a development stage biopharmaceutical company engaged in developing and commercializing therapeutics based on C1-esterase inhibitor (C1-INH) for the treatment of inflammatory diseases. Cinryze, the company’s lead drug candidate, is being developed for acute and prophylactic treatment of hereditary angioedema (HAE).

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Highlights

    Lev Pharmaceuticals in-licensed C1-INH from Sanquin in 2004. C1-INH is a human plasma protein that mediates inflammation and coagulation.

    Besides the current pipeline candidates, Lev Pharmaceuticals is also studying the use of C1-INH in the treatment of other inflammation-linked diseases such as gram-negative septicemia, inflammatory bowel disease, Alzheimer's disease and stroke.

    The company did not record revenues during the period 2002-2006 because the company currently does market any products, and has no other source of revenues. Lev Pharmaceuticals forecasts to derive 100% of its revenues from the sales of Cinryze. The total revenues will grow from $43 million in 2008 to $143 million in 2010.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company’s adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Overview 1
    Catalyst 1
    Summary 1
    Table of Contents 2
    Table of figures 3
    Table of tables 4
    Company Structure 5
    Company Overview and Key Facts 5
    Business Description 6
    Landmark Products and Services 6
    C1-INH technology 6
    History 7
    Company Financials 9
    Stock Market Performance 9
    P&L 10
    Balance Sheet 12
    Cash Flow 12
    Products & Services 13
    Pipeline Products 13
    In-house Pipeline 13
    Cinryze 13
    C1-INH 13
    AC Forecast Product Sales 14
    Competitors and Strategic Business Relationships 15
    Key Competitors 15
    Key Suppliers 15
    Shareholding Structure 16
    Strategy 17
    Corporate Strategy 17
    SWOT Analysis 18
    Overview 18
    Strengths 19
    C1-INH technology 19
    Weaknesses 20
    Inability to raise additional funds in capital markets 20
    Opportunities 21
    Cinryze 21
    Additional indication of C1-INH 21
    Threats 22
    Hurdles in launching Cinryze 22
    Uncertainty over market acceptance 22
    Value Chain Analysis 23
    Overview 23
    Product Development 23
    Sales 23
    Scorecard 24
    Overview 24
    Scorecard Analysis 24
    Key Employees 25
    List of Key Employees 25
    Key Employee Biographies 26
    Joshua D Schein 26
    Judson Cooper 26
    Henry M Dachowitz 27
    Scott Eagle 27
    Thomas Lanier 28
    Eric I Richman 28
    Douglas J Beck 29
    Matt Duffy 29
    Jason Bablak 29
    Bart Jones 30
    Ira N Kalfus 30
    Joseph Truitt 30
    Financial and Operational Overview 31
    Financial and Operational Overview 31
    APPENDIX 33
    Ask the analyst 33
    Datamonitor consulting 33
    Disclaimer 33
    List of Tables
    Table 1: Lev Pharmaceuticals- Key Facts 5
    Table 2: Lev Pharmaceuticals- Year-End Share Price and Market Capitalization, 2002-2006 ($) 9
    Table 3: Lev Pharmaceuticals- Key Events Impacting Share Price Performance 9
    Table 4: Lev Pharmaceuticals- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 10
    Table 5: Lev Pharmaceuticals- Balance Sheet 12
    Table 6: Lev Pharmaceuticals- Cash Flow 12
    Table 7: Lev Pharmaceuticals- In-house Pipeline Products 13
    Table 8: Lev Pharmaceuticals - Forecast Sales, 2006-2010 ($ Mn) 14
    Table 9: Lev Pharmaceuticals- Key Competitors 15
    Table 10: Lev Pharmaceuticals- Key Suppliers 15
    Table 11: Lev Pharmaceuticals- Key Shareholders 16
    Table 12: Lev Pharmaceuticals- SWOT Analysis Summary 18
    Table 13: Lev Pharmaceuticals- Value Chain Analysis 23
    Table 14: Lev Pharmaceuticals- Key Employees 25
    Table 15: Lev Pharmaceuticals - Financial and Operational Overview 31
    List of Figures
    Figure 1: Lev Pharmaceuticals- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 11